-
TEPROTUMUMAB FOR THYROID EYE DISEASE: UK KEY OPINION LEADER PERSPECTIVES TO INFORM A NICE HTA STRATEGY
Aug 11, 2026, 17:16 PM -
CAREGIVER IMPACTS OF ACUTE AND CHRONIC MIGRAINE: A LITERATURE-BASED CONCEPTUAL MODEL
Aug 11, 2026, 17:16 PM -
PATIENT-LEVEL SIMULATIONS IN NICE TECHNOLOGY APPRAISALS: HOW OFTEN ARE THEY USED AND WHY ARE THEY CHOSEN?
Aug 11, 2026, 17:16 PM -
MEASUREMENT PROPERTIES OF THE PATIENT-REPORTED IMPACT OF DERMATOLOGICAL DISEASES (PRIDD): A GLOBAL STUDY OF PATIENTS WITH ALOPECIA AREATA
Aug 11, 2026, 17:16 PM -
ESTABLISHING NON-INFERIORITY OF RITUXIMAB PLUS LENALIDOMIDE IN THE TREATMENT OF ADVANCED PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA
Aug 11, 2026, 17:16 PM -
FIVE-YEAR BLOOD PRESSURE TRAJECTORIES AND CUMULATIVE RISK OF SEVERELY UNCONTROLLED HYPERTENSION IN 67764 HYPERTENSIVE PATIENTS
Aug 11, 2026, 17:16 PM -
HERNIA RISK, DEPRIVATION AND FAIRER PREVENTION
Aug 11, 2026, 17:16 PM -
MIND THE DATA GAP: A CONCEPTUAL FRAMEWORK FOR PROXY-BASED HEALTHCARE COST ESTIMATION IN EUROPE
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS OF TEZEPELUMAB VERSUS DUPILUMAB AND MEPOLIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP) IN SPAIN
Aug 11, 2026, 17:16 PM -
IMPACT OF PRICING DYNAMICS AND REBATE TIMING ON REVENUE RELATIVE TO THE 30 MILLION THRESHOLD FOR ORPHAN DRUGS IN GERMANY: A PROBABILISTIC SCENARIO ANALYSIS
Aug 11, 2026, 17:16 PM -
REDEFINING THE VALUE OF PUBLIC-INTEREST REAL-WORLD DATA RESEARCH: A DECISION-ORIENTED FRAMEWORK FOR PHARMACEUTICAL STRATEGY
Aug 11, 2026, 17:16 PM -
MAKING RWE WORK FOR JCA: ALIGNING POLICY EXPECTATIONS AND METHODOLOGICAL RIGOR ACROSS EUROPE
Aug 11, 2026, 17:16 PM -
MEASURED BUT NOT USED: THE GAP BETWEEN OUTCOME MEASUREMENT AND PAYMENT IN VALUE-BASED CARDIOVASCULAR CARE ACROSS 15 EUROPEAN HEALTH SYSTEMS
Aug 11, 2026, 17:16 PM -
PIPELINE REVIEW OF TRADITIONAL SMALL MOLECULE ANTIBACTERIAL MEDICINES
Aug 11, 2026, 17:16 PM -
CAN A MODEL EXPLAINER AGENT ACCELERATE MANUFACTURER RESPONSES TO HEALTH TECHNOLOGY ASSESSMENT CLARIFICATION QUESTIONS?
Aug 11, 2026, 17:16 PM -
CHARACTERIZING THE CLINICAL AND HUMANISTIC BURDEN OF MYELOFIBROSIS: EVIDENCE FROM A SYSTEMATIC LITERATURE REVIEW
Aug 11, 2026, 17:16 PM -
HTA BODIES REQUEST FEWER THAN 50% OF GUIDELINE-DEFINED PICOS: EVIDENCE FROM EIGHT EU MARKETS AND LESSONS FOR EU JCA
Aug 11, 2026, 17:16 PM -
PRICING AN ORPHAN THERAPY WHEN COST-UTILITY ANALYSIS IS INFEASIBLE: A PRICE-EFFICACY FRONTIER FOR PRIMARY HYPEROXALURIA TYPE 1 IN MOROCCO
Aug 11, 2026, 17:16 PM -
RESPIRATORY SYNCYTIAL VIRUS- HEALTHCARE RESOURCE UTILIZATION IN BRAZILIAN CHILDREN <5 YEARS: SURVEILLANCE AND HOSPITAL DATA, 2022-2024
Aug 11, 2026, 17:16 PM -
TRANSLATION AND CULTURAL ADAPTATION OF THE EQ-5D-5L BOLT-ON TOOLBOX INTO MODERN STANDARD ARABIC FOR USE IN SAUDI ARABIA
Aug 11, 2026, 17:16 PM
